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Abstract
Background: An abdominal aortic aneurysm (AAA) is a focal dilation of the abdominal aorta and is associated with
a risk of fatal rupture. Experimental studies suggest that myo-inositol may exert beneficial effects on AAAs through
favourable changes to biological pathways implicated in AAA pathology. The aim of the Inositol in the MAnaGemENt
of abdominal aortic aneurysm (IMAGEN) trial is to assess if myo-inositol will reduce AAA growth.
Methods/design: IMAGEN is a multi-centre, prospective, parallel-group, randomised, double-blind, placebo-controlled
trial. A total of 164 participants with an AAA measuring≥ 30 mm will be randomised to either 2 g of myo-inositol or
identical placebo twice daily for 12 months. The primary outcome measure will be AAA growth estimated by increase
in total infrarenal aortic volume measured on computed tomographic scans. Secondary outcome measures will include
AAA diameter assessed by computed tomography and ultrasound, AAA peak wall stress and peak wall rupture index,
serum lipids, circulating AAA biomarkers, circulating RNAs and health-related quality of life. All analysis will be based on
the intention-to-treat principle at the time of randomisation. All patients who meet the eligibility criteria, provide written
informed consent and are enrolled in the study will be included in the primary analysis, regardless of adherence to
dietary allocation.
Discussion: Currently, there is no known medical therapy to limit AAA progression. The IMAGEN trial will be the first
randomised trial, to our knowledge, to assess the value of myo-inositol in limiting AAA growth.
Trial registration: Australian New Zealand Clinical Trials Registry, ACTRN12615001209583. Registered on 6
November 2015.
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Background
Abdominal aortic aneurysm (AAA) is a focal dilation of
the abdominal aorta with a maximum diameter ≥ 30 mm
[1]. The most recognised complication of AAA is aortic
rupture, the risk of which increases at larger diameters [1,
2]. Patients with AAA have at least a twofold increased
rate of cardiovascular events, particularly myocardial
infarction, compared with individuals with normal aortic
diameter [3]. AAAs can be readily identified when they are
small by ultrasound surveillance or incidental imaging. At
this stage, patients have minimal risk of AAA rupture and
can thus potentially be treated early [4–7]. There are, how-
ever, limited current means to effectively treat such patients
[1, 8, 9]. The only treatment currently available for AAA is
surgical repair, which is associated with significant mortality
(1–5%), peri-operative complications, in-hospital costs, and
the need for post-operative follow-up, imaging and, in some
cases, repeat surgery [1, 5, 7, 10–12]. Four randomised
controlled trials have demonstrated that early elective
surgery does not reduce mortality for patients with small
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(<55 mm) AAAs [4–7]. It is estimated that 50–70% of
small AAAs will eventually grow to a size at which surgi-
cal repair is indicated [5, 7, 13]. Effective medical therapies
administered to patients with small AAAs could prevent
or limit AAA growth, thereby reducing or avoiding the
need for surgery. Only a small number of randomised
controlled trials have been carried out to assess medical
therapies for AAA, and none have identified an effective
treatment [8, 9, 14]; however, a number of such trials are
ongoing [15].
Findings from previous studies suggest that increased
consumption of myo-inositol has the potential to target key
pathways implicated in AAA progression [16–19]. Myo-
inositol can be ingested from a number of foods and is
found in high concentrations in vegetables, nuts, whole
grains and fresh fruits [20]. Consumption of these foods
has been associated with reduced prevalence of AAA and
reduced incidence of cardiovascular events [21, 22]. Myo-
inositol is a key component of the cell membrane structure
and cell signalling pathways [23–25]. Myo-inositol and its
metabolites play an important role in the control of cell
proliferation, cell survival, matrix remodelling and inflam-
mation [23–31]. Inositol phosphates have been shown to
inhibit nuclear factor kappa-light-chain-enhancer of acti-
vated B cells (NF-κB) activation, which is recognised as a
master regulator of inflammation and matrix remodelling
[26]. Activation of NF-κB upregulates chemokines such as
C-C motif chemokine 22 (CCL22), matrix metalloprotein-
ases (MMPs) and cathepsins, which are all implicated in
AAA pathogenesis [32–37]. Inhibition of NF-κB has previ-
ously been demonstrated to inhibit AAA growth in pre-
clinical animal models [33, 36–38]. Inositol phosphates also
control the mechanistic target of rapamycin (mTOR) sig-
nalling pathway [39]. Inhibition of mTOR limits AAA
growth in pre-clinical rodent models by reducing aortic re-
cruitment of inflammatory cells and inhibiting production
of pro-inflammatory cytokines [40, 41]. Inositol phosphates
have also been shown to favourably influence the produc-
tion of bone proteins [42]. It has previously been reported
that bone proteins, including osteoprotegerin (OPG), osteo-
pontin (OPN) and sclerostin (SOST), are implicated in the
pathogenesis of AAA [34, 35, 43, 44]. Collectively, these
data suggest that myo-inositol has potential ability to limit
key pathological mechanisms involved in AAA, although
the effect of myo-inositol administration on AAA growth
has not previously been assessed.
Dietary supplementation with myo-inositol has previously
been examined in a number of patient groups, including
women with polycystic ovary syndrome and gestational dia-
betes, as well as patients with depression, with favourable
results [16, 17, 19, 45, 46]. Administration of doses of ~ 4 g
per day has been reported to reduce circulating concentra-
tions of pro-inflammatory cytokines such as resistin, as well
as to favourably modify circulating lipids by reducing
triglycerides and raising high-density lipoprotein (HDL)
cholesterol and phosphatidylcholine plasmalogen lipids
[16–19]. It has previously been reported that patients with
AAA have a distinct circulating pro-inflammatory and lipid
profile [47–50]. AAA is associated with high serum resistin,
triglycerides, linoleic acid-containing triacylglycerols and
diacylglycerols, and low serum HDL cholesterol [47–50].
Given the ability of myo-inositol to reduce inflammation
and favourably modify the lipid profile in other patients, it
is possible that this approach could have similar effects in
patients with AAA. Such effects would be expected to limit
the main complications in these patients, specifically AAA
growth and cardiovascular events.
The primary aim of the Inositol in the MAnaGemENt
of abdominal aortic aneurysm (IMAGEN) trial is to
determine if dietary supplementation with 2 g of myo-
inositol twice daily limits AAA growth over 12 months,
evidenced by limiting AAA volume assessed on the basis
of computed tomography (CT). The secondary aims of
the IMAGEN trial are to examine the effect of dietary
supplementation with 4 g of myo-inositol daily for
12 months on (a) AAA growth assessed by aortic diam-
eter measured by CT and ultrasound; (b) AAA peak wall
stress (PWS) and peak wall rupture index (PWRI) esti-
mated on the basis of CT; (c) lipid profile; (d) circulating
markers of inflammation, matrix remodelling and circu-
lating RNA profile; and (e) health-related quality of life.
Methods/design
Study design
IMAGEN is a multi-centre, prospective, parallel-group,
randomised, double-blind, placebo-controlled trial de-
signed to assess if dietary supplementation with 2 g of
myo-inositol twice daily for 12 months will reduce AAA
growth. The trial will be conducted at four sites in
Australia: The Royal Brisbane and Women’s Hospital,
Brisbane; Gosford Vascular Services, Gosford; The
Townsville Hospital, Townsville; and Mackay Base
Hospital, Mackay. This trial protocol is reported accord-
ing to the Standard Protocol Items: Recommendations
for Interventional Trials (SPIRIT) (see Additional file 1).
Only research personnel who are directly involved in the
recruitment and data collection aspect of the study will
have access to participants’ personal details. All case
report forms (CRFs), source documentation and samples
will be de-identified and coded with a study number,
according to good clinical practice (GCP) guidelines.
Participants
The IMAGEN trialists plan to enrol 164 participants
who have an asymptomatic infrarenal AAA measuring a
maximum diameter ≥ 30 mm on the basis of CT or
ultrasound, both of which will be performed as part of
the baseline assessments (see Fig. 1). Participants will be
Rowbotham et al. Trials  (2017) 18:547 Page 2 of 10
included only if they have a high likelihood of treatment
compliance over 12 months as determined by their treat-
ing physician or local study coordinator. IMAGEN will
not include patients with an existing indication for AAA
repair or expectation that this will be revised within
12 months. Additional exclusion criteria include previ-
ous reaction to myo-inositol supplementation, inability
to tolerate abdominal imaging, inability to provide blood
samples and previous abdominal aortic surgery. A full
list of inclusion and exclusion criteria is given in Table 1.
Randomisation
The randomisation scheme will be generated from Stata
code (StataCorp, College Station, TX, USA) and maintained
by the central clinical trial pharmacist. Randomisation to
myo-inositol or placebo will be stratified by study centre,
presence of diabetes and aortic diameter (30–34, 35–39,
40–44, 45–49 and ≥ 50 mm) as measured on ultrasounds.
Randomisation will be blocked in a 1:1 ratio (randomly to a
maximum block size of 8). The central and site trial man-
agers will be blinded to treatment allocation. Eligible and
consenting participants will be allocated to inositol or
placebo groups via a telephone call. Once an allocation
number is obtained, the trial supplement will be dispensed
by the local clinical trial pharmacist (after randomisation
Fig. 1 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure: schedule of enrolment, interventions, and assessments.
ABI Ankle-brachial index, BP Blood pressure, CT Computed tomography
Table 1 Patient eligibility criteria
Inclusion criteria
• Ability to provide written informed consent
• Diagnosis with an infrarenal AAA measuring a maximum diameter
≥ 30 mm based on CT or ultrasound
• No current indication for AAA repair according to the treating
physician or expectation that this will be revised over 12 months
• High likelihood of treatment compliance over 12 months according
to the treating physician and local study coordinator
• Aged≥ 50 years
Exclusion criteria
• Symptomatic, ruptured or mycotic AAA
• Contraindication to the study protocol:
○ Previous reaction to myo-inositol supplementation
○ Inability to tolerate abdominal imaging
○ Inability to provide blood samples for safety and outcome analysis
• Previous abdominal aortic surgery
• Current or planned participation in another randomised trial
• Treating physician feels the patient is not suitable for trial entry
CT Computed tomography, AAA Abdominal aortic aneurysm
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and at the 6-month time point). Allocation concealment
will be achieved by using a central randomisation centre
and employing identical packaging of intervention and
placebo. Participants, investigators and outcome assessors
will be blinded to treatment allocation. In the case of an
emergency where breaking of the group allocation blinding
is required, the local study centre clinical trial pharmacist
will be contacted.
Interventions
Participants in the intervention group will receive four
500-mg capsules of myo-inositol, which is to be taken
orally at 08:00 and 20:00 daily. This dose has been used
in previous clinical trials in other patient groups and is
well tolerated over 12 months, with no side effects
reported [16–19, 45]. Furthermore, this dose has been
reported to favourably modify lipid profile and reduce
circulating concentrations of pro-inflammatory cytokines
in other patient groups [16–19, 45], effects that would
be expected to limit AAA growth [1, 8, 51]. Participants
will be instructed to avoid ingesting aperients or coffee
within 1 h of taking the study supplement because
these may interfere with myo-inositol absorption [52].
Participants in the control group will receive four 500-
mg capsules of inert cellulose powder, which is to be
taken orally at 08:00 and 20:00 daily. It will be packaged
in an identical fashion to the intervention drug by
Pharmaceutical Packaging Professionals (Thebarton,
Australia), an established current good manufacturing
practice facility.
Participant time line
The overall design of the IMAGEN trial is shown in Fig. 2.
At vascular outpatient clinics, potential participants will be
identified and pre-screened for suitability, and, if appropri-
ate, informed consent will be obtained, after which they will
be formally assessed against the eligibility criteria (Table 1).
Individuals will undergo a medical examination, anthropo-
metric assessment (height, weight, waist and hip circumfer-
ence), resting blood pressure, heart rate and ankle-brachial
index assessments, questionnaires (health-related quality of
life and food frequency), a 24-h dietary recall survey, and
collection of blood samples for measurement of full blood
count (haemoglobin, red cell count, white cell count, plate-
lets, neutrophils, lymphocytes, monocytes, eosinophils, ba-
sophils), urea and electrolytes (sodium, potassium,
creatinine, estimated glomerular filtration rate, albumin,
total bilirubin, urea, chloride, bicarbonate), liver function
tests (alanine transaminase, aspartate aminotransferase,
γ-glutamyl transpeptidase, lactate dehydrogenase), fasting
lipids (cholesterol, triglyceride, HDL cholesterol and low-
density lipoprotein [LDL] cholesterol), and fasting glucose.
Serum, plasma and whole blood will also be collected for
assessment of circulating proteins and genetic (DNA and
RNA) analyses. Investigational blood samples will be
collected into the following tubes: 2 x 5 ml SST, 2 x 4 ml
ethylenediaminetetraacetic acid, 1 x 4 ml Sodium Citrate
and 1 x 2.5 ml PAXgene (Qiagen, Valencia, CA, USA).
Blood samples will be processed according to standard
operating procedures and shipped to the study centre in
Townsville. Baseline CT and ultrasound will be performed
for detailed measurements of AAAs.
Eligible and consenting patients will be randomised to
receive either 2 g of myo-inositol or identical placebo
twice daily for 12 months. Participants will be contacted
by telephone call at 1 month after commencing the trial
medication and asked about adherence to the study drug
regimen as well as adverse and clinical events. Phone
consultations will be repeated at 3 and 9 months.
Follow-up visits will occur at 6 and 12 months, when
participants will receive ongoing questionnaires, clinical
examinations, blood tests and imaging according to
Fig. 1. The occurrence of adverse and clinical events and
adherence to the study drug regimen will also be
assessed. All participants, including those in whom
medication is ceased, will be invited to follow-up visits
for the duration of the study in the absence of AAA
repair. Final follow-up will occur at 12 months after
commencement of medication, at which point the
participant will discontinue the prescribed medication
and return any unused medication.
Compliance
Previous studies suggest that compliance with dietary sup-
plementation of 4 g of myo-inositol daily is excellent [19,
45]. To facilitate compliance, a number of techniques will
Fig. 2 Design of the Inositol in the MAnaGemENt of abdominal
aortic aneurysm (IMAGEN) trial. AAA Abdominal aortic aneurysm, CT
Computed tomography, PWRI Peak wall rupture index, PWS Peak
wall stress
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be used, including providing participants with the
telephone number of the local trial coordinator with
instructions to contact in the event of possible supplement-
related problems or consideration of discontinuation. In
this event, arrangements will be made for the participant to
be reviewed by the study physician to ascertain if discon-
tinuation is required. The trial will also use a reminder
system to facilitate compliance. This will consist of
reminders from the local trial coordinator to each partici-
pant at 1, 3, 6 and 9 months after randomisation to check
and encourage compliance. Participants will be provided
with a compliance diary at the commencement of the trial.
Participants will bring their diaries and remaining supple-
ment capsules to review appointments at 6 and 12 months,
and compliance will be checked by capsule and bottle
counting. Where < 95% of capsules were taken since the last
review, the study coordinator will attempt to work with the
participant to identify the issues which have impacted
compliance and provide suggestions on how to overcome
these issues in future.
Outcome assessment
Outcome assessment will be performed at baseline, 6 and
12 months. Participants will be imaged by ultrasound at
baseline, 6 and 12 months and by aortic CT at baseline
and 12 months. Blood will be collected at baseline, 6 and
12 months and will be used to assess biomarker outcomes
and safety.
Primary efficacy endpoint
The primary outcome measure will be AAA growth
estimated by increase in total infrarenal aortic volume
on the basis of CT. Previous studies indicate this is a
reproducible and sensitive measure of AAA growth
[53]. A standardised and established CT imaging proto-
col will be employed at all four centres, as previously
described [53–55]. All CT images will be transferred to
the central imaging centre in Townsville, where image
quality will be confirmed. Total infrarenal aortic
volume will be measured from the level directly below
the renal arteries to the bifurcation using the Philips
IntelliSpace Portal 7.0 (Philips Clinical Informatics,
Amsterdam, The Netherlands), as previously described
[53]. Central reading of the CT images will be
performed by a single experienced observer who has
previously been shown to have excellent imaging
analysis reproducibility. The repeatability of central
readings will be checked intermittently during the cen-
tral reading period, which will span the duration of the
trial.
Secondary efficacy endpoints
Secondary outcome measures reflect the proposed
mechanism of action of myo-inositol, are important
and relevant clinical events, and are implicated in
AAA growth.
Maximum AAA diameter assessed by CT
Maximum AAA diameter is the most validated marker of
AAA rupture risk and currently the main determinant of
when patients are selected for intervention [4–7, 56].
Maximum outer wall to outer wall AAA diameter will be
assessed in anteroposterior (AP) and transverse orthogonal
planes centrally from reconstructed aortic CT images
obtained using a previously published reproducible proto-
col [53, 57–59]. The assessment will be performed by a
single experienced observer who has previously been
shown to have excellent imaging analysis reproducibility.
Maximum AAA diameter assessed by ultrasound
Participants will be assessed by ultrasound in the morning,
having fasted from midnight. Maximum outer wall–to-
outer wall diameter assessed in an AP orthogonal plane
will be measured by experienced sonographers using a
3.75-MHz transducer and ultrasound machines present in
the vascular laboratories of each centre (Toshiba Capasee,
Toshiba Medical Systems, Duluth, GA, USA; Philips HDI
5000, Philips Medical Systems, Norcross, GA, USA;
LOGIQ E9, GE Healthcare Life Sciences, Chicago, IL,
USA), as previously described [44, 60]. The maximum AP
inner wall-to-inner wall, leading edge wall-to-leading edge
wall and outer wall-to-outer wall measurements on the
largest AAA ultrasound image recorded at each time
point will be centrally assessed by a single experienced ob-
server who has previously been shown to have excellent
imaging analysis reproducibility.
AAA PWS and PWRI
These parameters will be estimated by a single investigator
using the A4research software (VASCOPS GmbH, Graz,
Austria) with a reproducible and previously validated
technique [2, 61, 62]. A 3D reconstruction of the AAA is
produced from the CT images, and a fine element analysis
mesh is automatically generated by the software. This is
used to estimate the PWS and PWRI, providing a surrogate
marker of rupture risk [61, 62].
Serum lipids
Total cholesterol, triglycerides, LDL cholesterol and
HDL cholesterol concentrations will be assessed using
automated assays (Hitachi 917; Roche Diagnostics
GmbH, Mannheim, Germany) with serum obtained from
patients who have fasted overnight. The inter-assay co-
efficient of variation (CV) for these assays has been
shown to be between 2% and 5% in our previous studies
[49, 50].
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Circulating AAA biomarkers
The following biomarkers have been selected on the
basis of their reported association with AAA and previ-
ous data suggesting they may be favourably modified by
myo-inositol supplementation [16–19, 23–46, 63, 64]:
serum resistin, plasma interferon γ, plasma CCL22,
plasma D-dimer, plasma MMP-2, plasma MMP-9,
plasma cathepsin S, serum OPN, plasma OPG and
serum SOST. Concentrations will be measured using
established commercial enzyme-linked immunosorbent
assays (R&D Systems, Minneapolis, MN, USA) accord-
ing to the manufacturer’s instructions and expressed as
nanograms per millilitre. Intra-assay and inter-assay
CV for all these assays are between 3% and 6% in our
laboratory (concordance correlation coefficient ~ 0.999)
[32, 35, 44, 47, 63–65].
Profiling of circulating RNAs
Blood will be collected into PAXgene tubes at baseline
and at 6 and 12 months. RNA will be extracted from
these samples and used to assess the expression profile
of circulating cells. Established techniques will be used
to assess expression profile, including microarrays, next-
generation sequencing and RT-PCR as we have previ-
ously reported [66–68].
Health-related quality of life
Health-related quality of life will be assessed using the
36-item Short Form Health Survey (SF-36) completed at 0,
6 and 12 months and has previously been validated for use
in patients with AAA [69]. Additional outcome measures
include dietary analysis assessed by means of a food
frequency questionnaire and 24-h recall interview at
baseline and at 6 and 12 months, as previously described
[70]. Finally, acute cardiovascular events, requirement for
peripheral arterial intervention, AAA rupture, all-cause
mortality, changes in background medication and with-
drawal from the study dietary supplement (by indication)
will be recorded. These data will be recorded through pa-
tient interview every 6 months, chart reviews and linked
data, as previously described [71–73].
Participant safety
Previous trials using dietary supplementation with 4 g of
myo-inositol daily suggest it is associated with no ill ef-
fects. There have been no reports of excess gastrointes-
tinal, cardiovascular, respiratory or cutaneous symptoms
in those randomised to myo-inositol compared with pla-
cebo [16, 17, 19, 45]. Patient safety will be assessed at 6
and 12 months following randomisation by assessment
of blood pressure and heart rate; laboratory parameters,
including serum chemistry (liver function tests, glucose,
creatinine, sodium, potassium, chloride, bicarbonate, cal-
cium and phosphorous) and haematology (haemoglobin,
differential white blood cell and platelet counts); and
questions regarding adverse events (AEs). Participants
will be contacted by telephone at 1, 3 and 9 months
following randomisation to enquire about AEs. Further-
more, participants will be provided with full contact
details of the site trial coordinators with instructions to
contact them in the event of any AEs. All AEs will be
reported via standardised forms to the coordinating
centre and carefully monitored throughout the study.
Serious adverse events (SAEs) will be defined according
to current Australian GCP guidelines and will be
reported according to the National Health and Medical
Research Council (NHMRC) Safety Monitoring and
Reporting in Clinical Trials Involving Therapeutic Goods
guidelines (November 2016) [74–77]. All SAEs will be
reviewed by the safety committee, which will consist of
two independent vascular surgeons. The safety commit-
tee will concentrate on events which could be AAA-
related, such as sudden death due to AAA rupture, or
events that could be related to myo-inositol, such as
gastrointestinal problems or electrolyte disturbances.
Expected AAA rupture rates for small AAAs are ~ 1–2%
per year [4–7]. Rupture rates > 5% per year will be con-
sidered cause for concern. In this instance, all other out-
come data from the study will be analysed. AAA growth
will be compared between groups using these data. The
final decision to stop the study will take into account
AAA ruptures, AAA growth data and any other serious
complications. On the basis of findings, the safety commit-
tee will report their decision to the steering committee.
Interim analysis
An interim analysis assessing trial efficacy will be con-
ducted once approximately one-third of participants have
completed 12 months of myo-inositol treatment. In this
analysis, we will assess changes in AAA volume and diam-
eter over time to determine whether (a) a suggested differ-
ence in AAA growth between participant groups is
observed and (b) whether a priori calculated sample sizes
will provide adequate power to detect any observed differ-
ences in AAA growth. These findings will be conducted by
an independent statistician using dummy-coded data to
separate patients into drug or placebo groups (e.g., X and
Y), thereby maintaining trial blinding and minimising
potential bias. In the instance of a clear difference in AAA
growth rate between groups, the statistician will liaise with
the dispensing pharmacist to determine if participants
receiving inositol exhibit faster AAA growth than control
participants. Findings from this interim analysis will be
reported to members of the steering committee, who will
consider concluding the trial if either (a) myo-inositol
administration appears to be associated with accelerated
AAA growth (ethical assessment) or (b) revised sample size
calculations based on observed AAA growth for the cohort
Rowbotham et al. Trials  (2017) 18:547 Page 6 of 10
suggest that group sizes need to be increased beyond what
can reasonably be achieved (futility assessment).
Sample size and power calculations
It is hypothesized that dietary supplementation with 4 g of
myo-inositol daily for 12 months will reduce AAA growth
by 40%, as evidenced by limiting increase in AAA volume
from 8.1 ± 6.9 cm3 to 4.9 ± 6.9 cm3. Estimated outcomes
for the control group are based on CT volume measured
in a pilot cohort [53]. An effect size of 40% is based on the
consideration of outcomes likely to be required for clinical
efficacy. For example, if myo-inositol reduced annual in-
crease in AAA size by 40%, the estimated time for an
AAA initially measuring 40 mm to reach the commonly
employed intervention level of 50 mm would be increased
from 5 to ~ 7 years. Given that the annual mortality rate
due to non-AAA-related causes is ~ 5% in patients with
small AAAs, this reduction in growth could be expected
to result in ~ 10% less patients requiring interventions
over 5 years. This has significant potential social and eco-
nomic benefit, with a possible cost saving of ~ $1 million
per year [5, 6, 12]. On the basis of these estimated out-
comes, 74 participants per group are required (80% power,
α = 0.05) to detect the hypothesized reductions in AAA
volume. Using data from a pilot cohort, it is estimated that
this sample size will have a power of ~ 85% to detect a
40% reduction in orthogonal AAA diameter increase, as-
suming that the SD for the intervention group reduces in
line with the mean. Allowing for a dropout rate of 10%, a
total of 164 patients will be required. Sample sizes were
calculated using G*Power 3.1 software.
Data analysis
Analysis of primary and secondary endpoints will be based
on intention to treat at the time of randomisation. All par-
ticipants who meet the eligibility criteria, provide written
informed consent and are enrolled in the study will be in-
cluded in the primary analysis, regardless of adherence to
supplement allocation. The efficiency of randomisation
will be assessed by comparing the distribution of recog-
nized determinants of AAA growth, such as initial AAA
diameter, and background medication between the inter-
vention and control groups.
The primary efficacy parameter is the between-group
difference in mean AAA growth over 12 months as esti-
mated by infrarenal aortic volume measured by CT. If
there were to be no dropouts, the observed mean AAA
volume increase over 12 months would be compared
using a two-sample t test. However, it is expected that
10% of participants will drop out. AAA growth will there-
fore be analysed using a linear mixed model, specifying
zero difference between treatment groups at baseline. The
model will have two repeated dependent measurements.
The fixed part of the model will contain the following
covariates: time for CT measurement as a categorical vari-
able, treatment, and interaction between treatment and
CT time. The covariance part of the model will constitute
a linear covariance matrix containing the following param-
eters: variance of CT measurements and covariance
parameters. Without reference to the fixed part of the
model, the goodness of fit of the assumed covariance
model will be investigated. If necessary, the model will be
extended with additional terms. The analysis will be
performed using the PROC MIXED procedure in SAS
software (SAS Institute, Cary, NC, USA), which is capable
of fitting arbitrary linear covariance matrices. The main
null hypothesis that will be tested is based on the treat-
ment effect as estimated by this model at 12 months on
CT measurements.
Secondary outcomes, including AAA diameter (CT
and ultrasound), AAA PWS and PWRI, serum lipids,
AAA biomarkers, RNA expression profile and SF-36
scores will be compared between the intervention and
control groups using a linear mixed effect model similar
to that described for the primary outcome. A number of
additional analyses will also be performed, depending on
the results of the primary analyses described above.
These may include adjusted analyses using linear and
logistic regression, such as where any important differ-
ence between the intervention and control groups are
identified and Kaplan-Meier analyses to compare cardio-
vascular events and AAA repair rates.
Trial and data organisation
This project has been developed through collaboration be-
tween experts in the biology and clinical management of
AAA, aortic imaging and clinical trials. The trial steering
committee comprises senior vascular investigators from the
centres involved and experts in drug trials and data analysis.
This will be the main policy- and decision-making commit-
tee for the study and will meet by teleconference on a quar-
terly basis. The clinical trial randomisation centre will be
located at the NHMRC Centre for Cardiovascular Research
& Education in Therapeutics at Monash University. A
study coordinator located at James Cook University will
coordinate activities across all the participating sites, assist-
ing with local ethics reports, and communicating with the
local sites, including updates and maintenance of the trial
website, central computerised randomisation, data collec-
tion, entry and processing. Trial coordination will be facili-
tated by a clinical trial network established by the National
Health and Medical Research Council-funded Centre of
Research Excellence for Peripheral Arterial Disease. To de-
termine whether important differences in the incidence of
significant AEs exist between the treatment arms, an inde-
pendent safety committee has been formed. The core im-
aging/biomarker laboratory located in Townsville will
receive DICOM images of the CT scans and frozen serum/
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plasma to assess the CT and biomarker outcomes. Baseline
and follow-up data will be collected on CRFs. All data will
be stored in a central database and examined for data qual-
ity. A publications committee will oversee the preparation
of reports arising from the study.
Discussion
One of the main risk factors for AAA is age, with the
problem being much more common in the > 60-year-old
age group [1, 8]. With the continued expansion in the
elderly population, the number of AAA operations can
be expected to continue to increase [78]. Alternative
forms of treatment for AAA are urgently needed, ideally
those which are non-invasive, suitable for the older age
group and cost-effective. The IMAGEN trial will be the
first randomised trial, to our knowledge, to assess the
value of myo-inositol in limiting AAA growth. To date,
only two trials of medical treatment of AAA with suffi-
cient sample size have been published, and both had
negative findings [9, 79]. If the present hypotheses are
confirmed, it is estimated that myo-inositol could lead
to a reduction in AAA surgery of ~ 1–2% per year at the
expense of a low-cost dietary supplement. The results of
this trial could markedly change the clinical manage-
ment of small AAAs, which currently consists of ultra-
sound surveillance. This study will also provide
important information on (a) biomarkers which predict
responsiveness to myo-inositol, (b) the effect of myo-
inositol on cardiac events and (c) biomarkers for AAA
growth. The IMAGEN trial may identify circulating
markers which can be used to guide management of
small AAA and selection for therapy by drugs or surgical
interventions.
Trial status
Participants are currently being recruited.
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Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 122 kb)
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